Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldoxorubicin + gemcitabine
- Development stage
- Unknown
- Lead developer
- LadRx
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Aldoxorubicin + gemcitabine** is an investigational combination therapy composed of aldoxorubicin, a tumor-targeted prodrug of doxorubicin, and gemcitabine, a nucleoside analog antimetabolite. Aldoxorubicin covalently binds to albumin and is released under acidic conditions within tumors, delivering doxorubicin to malignant tissue with reduced systemic cardiotoxicity. Gemcitabine is phosphorylated intracellularly to active metabolites that inhibit DNA synthesis, leading to cell death. This combination has been evaluated in early-phase trials for relapsed or refractory metastatic solid tumors, seeking to leverage potentially synergistic antitumor activity, with dose-limiting toxicities similar to those of the parent drugs.
- Other names
- aldoxorubicin plus gemcitabine
02
Targets
RNR (Ribonucleotide reductase)CMPK1 (Deoxycytidylate kinase)DNA polymerase familyTOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on aldoxorubicin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldoxorubicin + gemcitabine.